A new look at the heart in diabetes mellitus: From ailing to failing

Diabetologia

Volumn 43, Issue 12, 2000, Pages 1455-1469

  Standl, E ^a   Schnell, O ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

Acute coronary syndrome; Autonomic neuropathy; Cardiac sympathetic dysfunction; Congestive heart failure; Coronary blood flow reserve; Endothelial activation; Myocardial infarction; Nitric oxide; Protein kinase C

Indexed keywords

NITRIC OXIDE; PROTEIN KINASE C;

ATHEROSCLEROTIC PLAQUE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; DISEASE PREDISPOSITION; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC TONE; TREATMENT PLANNING; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEART; HEART DISEASES; HUMANS;

EID: 0034435148     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051556     Document Type: Review

References (156)

1. The impact of diabetes mellitus on survival after myocardial infarction. Can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study
2. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes
3. Diabetes as a risk factor for MI: Population and gender prespectives
4. Effect of diabetes mellitus on short- and longterm mortality rates of patients with acute myocardial infarction: A statewide study
5. The relation of diabetes to the severity of acute myocardial infarction and postmyocardial infarction survival in Mexican-Americans and non-Hispanic whites: The Corpus Christi Heart Project
6. Angiografic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-I experience
7. Impact of mortality after the first myocardial infarction
8. Diabets mellitus and macrovascular complications. An epidemiological perspective
9. Mortality and survival in Type II (non-insulin-dependent) diabetes mellitus
10. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial
11. Diabetic cardiomyopathy: A unique entity or a complication of coronary artery disease?
12. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction
13. Heart disease in diabetes mellitus
14. Diabetes mellitus and cardiac function
15. Mortality from coronary heart disease subjects with Type II diabetes and in non-diabetic subjects with and without prior MI
16. Zur überlebensdauer von typ-II-diabetikern. Ergebnisse einer 20jährigen follow-up-studie in Berlin Ost
17. The diabetes-related risk of MI in a Southern German population: Results of the MONICA Augsburg studies 1985-1994
18. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents
19. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
20. Restenosis after percutaneous transluminal angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung and Blood Institute
21. Restenosis rates in diabetic patients: A comparison of coronary stenting and ballon angioplasty in native coronary vessels
22. Coronary angioplasty outcomes in the Healthcare Cost and Utilization Project 1993-1994
23. Restenosis after arterial injury caused by stenting in patients with diabetes mellitus
24. Predictive factors of restenosis after coronary stent placement
25. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial
26. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with mulitivessel coronary artery disease
27. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
28. Predictors of low cardiac output syndrome after coronary artery bypass
29. The optimal mode of coronary revascularisation for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery
30. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: A serial intravascular ultrasound study
31. Proteinuria: Value as predictor of cardiovascular mortality in insulin-dependent diabetes mellitus
32. Incidence of cardiovascular disease in Type I (insulin-dependent) diabetic patients with and without diabetic nephropathy in Finland
33. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
34. Tight blood pressure control and risk of complications in macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
35. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
36. Treatment of isolated hypertension in the elderly: Further evidence from the systolic hypertension in Europe (Syst-Eur) trial
37. Isolated hypertension in the elderly: Lessons from clinical trials and future directions
38. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
39. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
40. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
41. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Sub-group analyses in the cholesterol and recurrent events (CARE) trial
42. Factors that influence outcome in diabetic subjects with myocardial infarction
43. Predictors of a lethal outcome of myocardial infarctions in patients with type-2-diabetes mellitus
44. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients
45. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus
46. Enhanced myocardial performance with intensive insulin treatment during acute coronary events
47. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction: Relation to myocardial ischemia and infarct size
48. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term Type I diabetic patients with and without ECG-based autonomic neuropathy
49. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia
50. 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients
51. On the significance of new diagnostic approaches to cardiac autonomic neuropathy in Type 1 diabetes
52. Cardiac sympathetic dysinnervation in diabetes
53. Neurologische erkrankungen
54. Nerve glucose, fructose, sorbitol, myo-inositol and fibre degeneration and regeneration in diabetic autonomic neuropathy
55. Advanced glycosilation end products in tissue and the biochemical basis of diabetic complications
56. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy
57. Mitogen-activated protein kinases as glucose transducers for diabetic complications
58. Vascular factors in diabetic neuropathy
59. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients
60. Autoantibodies to sympathetic ganglia, GAD, or tyrosine phosphatase in long-term IDDM with and without ECG-based cardiac autonomic neuropathy
61. Evidence for specific autoimmunity against sympathetic and parasympathetic nervous tissues in Type 1 diabetes mellitus and the relation to cardiac autonomic dysfunction
62. Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus
63. Cardiac autonomic dysfunction: No association with autoantibodies against autonomic nervous tissues
64. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using (1231) metaiodobenzylguanidine
65. Myocardial m(123I)iodobenzylguanidine scintigraphy for the assessement of adrenergic cardiac innervation in patients with IDDM
66. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic dysinnervation and its relation to autonomic dysfunction and silent myocardial ischemia
67. Diagnosis of cardiovascular autonomic neuropathy in diabetes
68. Diagnosis and management of diabetic autonomic neuropathy
69. Current clinical applications of heart rate variability
70. Sympathovagal balance: A critical appraisal
71. Is undetected autonomic dysfunction responsible for sudden death in type 1 diabetes mellitus? The 'dead in bed' syndrome revisited
72. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study
73. Myocardial imaging in man with I-123-metaidobenzylguanidine
74. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man
75. Myocardial kinetics of carbon-11-meta-hydroxyephedrine (HED): Retention mechanisms and effects of norepinephrine
76. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine
77. Cardiac sympathetic imaging with radioionated metaiodobenzylguanidine (MIBG)
78. Imaging of myocardial sympathetic innervation with metaiodobenzylguanidine
79. Noninvasive assessment of cardiac diabetic neuropathy by C11 hydroxyephedrine and positron emission tomography
80. Quantitative Auswertung von 201Tc-Myocardsszintigrammen in SPECT
81. Role of transmitter uptake mechanisms in synaptic neurotransmission
82. Metabolism of iodine-131-metaiodobenzylguanidine in patients with metastatic pheochromocytoma
83. Investigation of parasympathetic and sympathetic cardiac innervation in diabetic neuropathy
84. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin dependent (Type 1) diabetes mellitus
85. Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (Type 1) diabetes mellitus at one-year follow-up
86. Scintigraphically assessed cardiac sympathetic dysinnervation in poorly controlled type 1 diabetes mellitus: One-year follow-up with improved metabolic control
87. Perspectives in diabetes: Clinical trials of diabetic neuropathy: Past, present, and future
88. Unterschiede in der kardialen autonomen Dysinnervation bei Typ-I- und Typ-II-Diabetes
89. A comparison of diabetic polyneuropathy in Type II diabetic BBZDR/Wor rats and in Type I diabetic BB/Wor rats
90. Pathology of autonomic neuropathy in diabetes mellitus
91. Diabetes and autonomic neuropathy: An immunological association?
92. Anti-adrenal medullary antibodies in IDDM subjects and subjects at high risk of developing IDDM
93. Antisympathetic ganglia autoantibodies and postural blood pressure in IDDM subjects of varying duration and patients at high risk of developing IDDM
94. Autoantibodies to nervous structures are associated with autonomic neuropathy in Type I (insulin-dependent) diabetes mellitus
95. Autonomic nerve antibodies and autonomic nerve function in type 1 and type 2 diabetic patients
96. Reproducibility and persistance of neutral and adrenal autoantibodies in diabetic autonomic neuropathy
97. Endothelial Function in health and disease: New insights into the genesis of cardiovascular disease
98. Platelet enzyme activities in diabetes mellitus in relation to endothelial damage
99. Endothelin: Emerging role in diabetic vascular complications
100. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
101. Insulin, nitric oxide and the sympathetic nervous system: At the crossroads of metabolic and cardiovascular regulation
102. Nitric oxide and vascular responses in Type I diabetes
103. Nitric oxide, cytokines and free radicals in diabetic vascular disease. Diabetes in the new millenium
104. Endothelial dysfunction: Does it matter? Is it reversible?
105. Impairment of endothelium dependent relaxation in the diabetic rat heart
106. Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta
107. Effect of elevated glucose on cyclic GMP and eicosanoids produced by porcine aortic endothelium
108. Cellular and molecular mechanisms in the macroangiopathy of diabetes
109. Advanced endothelial dysfunction in type 1 diabetes with autonomic neuropathy
110. Effects of cardiac sympathetic innervation on coronary blood flow
111. Cardiological applications of nuclear medicine
112. Exercise echocardiography or exercise SPECT imaging?
113. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus
114. Coronary flow reserve is reduced in young men with IDDM
115. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus
116. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy
117. Coronary vasomotion in response to sympathetic stimulation in humans: Importance of the functional integrity of the endothelium
118. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation
119. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: Cohort study
120. QTc interval and scintigraphically assessed myocardial perfusion in newly diagnosed and long-term type 1 diabetes mellitus
121. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells
122. Pathobiology of endothelial and other vascular cells in diabetes mellitus. Call for data
123. Allgemeiner überblick über die angiopathien
124. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practioner Project
125. Protein kinase C
126. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
127. Protein kinase C and lipid signaling for sustained cellular responses
128. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
129. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
130. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
131. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products
132. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration
133. Impaired nitric oxide release by glomeruli from diabetic rats
134. Targeted overexpression of protein kinase C isoform in myocardium causes cardiomyopathy
135. Increased protein kinase C activity and expression of Ca2 + -sensitive isoforms in the failing human heart
136. Impaired translocation of protein kinase C activity in human non-insulin-dependent diabetes mellitus
137. Activation of human platelet protein kinase C-β2 in vivo in response to acute hyperglycaemia
138. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor
139. Microalbuminuria in a random cohort of recently diagnosed Type II (non-insulin-dependent) diabetic patients living in the Greater Munich Area
140. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data of 20 studies of 95,783 individuals followed for 12.4 years
141. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
142. Hyperglycemia and cardiovascular disease in type 2 diabetes
143. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
144. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus
145. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complication Trial
146. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
147. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
148. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infraction (DIGAMI Study): Effects on mortality at 1 year
149. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
150. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction
151. Metabolic modulation of acute myocardial infarction - The ECLA Glucose-Insulin-Potassium Pilot Trial
152. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: A 4-year prospective study in IDDM patients
153. Failure of improved glycemic control to reverse diabetic autonomic neuropathy
154. Effect of pancreatic and/or renal transplantation on diabetic autonomic neuropathy
155. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life